Inhibition of HIV-1 infectivity by low molecular weight heparin: Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS

International Journal of Clinical and Laboratory Research

Volumn 26, Issue 2, 1996, Pages 124-131

  Howell, A L ^a,b   Taylor, T H ^a,b   Miller, J D ^b   Groveman, D S ^b   Eccles, E H ^b   Zacharski, L R ^a,b  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Acquired immunodeficiency syndrome; Heparin; Human immunodeficiency virus 1

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029764805     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02592355     Document Type: Article

References (38)

1. Capon D, Chamow S, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn R, Lucas C. Wurm FM, Groopman JE, Broder S, Smith DH. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989; 337 525.
2. Daar ES, Li XL, Moudgil T. Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type I isolates. Proc Natl Acad Sci USA 1990; 87: 6574.
3. Bagasra O, Whittle P, Heins B, Pomerantz RJ. Anti-human immunodeficiency virus type 1 activity of sulfated monosaccharides: comparison with sulfated polysaccharides and other polyions. J Infect Dis 1991; 164: 1082
4. Bagasra O, Lischner HW. Activity of dextran sulfate and other polysaccharides against human immunodeficiency virus. J Infect Dis 1988; 158: 1084.
5. Ito M, Baba M, Sato A, Pauwels R, De Clercq E, Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV-1) in vitro. Antiviral Res 1987; 7: 361.
6. Nakashima H, Matsui T, Yoshida O. A new anti-human immunodeficiency virus substance, glycyrrhizin sulfate: endowment of glycyrrhizin with reverse transcriptase inhibitory activity by chemical modification. Jpn J Cancer Res 1987; 78: 767.
7. Nakashima H, Kido Y, Kobayashi N, Motoki Y, Neushul M, Yamamoto N. Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae. Antimircrob Agents Chemother 1987; 31: 1524.
8. Ueno R, Kuno S, Anti-HIV-1 synergism between dextran sulphate and zidovudine. Lancet 1987; II: 796.
9. Baba M, Snoeck R, Pauwels R, De Clercq C Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus. vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1988; 32: 1742.
10. Ueno R, Kuno S. Dextran sulphate, a potent anti-HIV-1 agent in vitro having synergy with zidovudine. Lancet 1987; I: 1379.
11. Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, Bell KM. Lorentsen KJ. Hendrix CW. Petty BG. Lietman PS. Pharmacokinetics, toxicity. and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991; 35: 2544.
12. Lorentsen K, Hendrix C, Collins J, Kornhauser D, Petty B. Klecker R, Flexner C, Eckel R, Lietman P. Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med 1989; 111: 561.
13. Abrams D, Kuno S, Wong R, Jeffords K, Nash M, Molaghan J, Gorter R, Ueno R. Oral dextran sulfate (UA 001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989; 110: 183.
14. Hirsh J, Levine M. Low molecular weight heparin. Blood 1992; 79: 1.
15. Boyum A. Isolation of lymphocytes, granulocytes. and macrophages. Scand J Immunol 1976; 5 [Suppl 5]: 9.
16. Howell AL, Guyre PM, You K-S, Fanger MW. Targeting HIV-1 to FcγR on human phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells. J Leukoc Biol 1994; 55: 385.
17. Connor RI, Dinces NB, Howell AL, Romet-Lemonne J-L, Pasquali J-L, Fanger MW. Fc receptors for IgG (FcγR) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type l (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the FcyR. Proc Natl Acad Sci USA 1991; 88: 9593.
18. Castro K, Ward J, Slutsker L, Buehler J, Jaffe H, Berkelman R. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and mortality weekly. Report 1992; 41 (RR-17): 1.
19. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol 1991; 29: 676.
20. Baba M, Schols D, Pauwels R, Nakashima H, De Clercq E. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards AIDS chemotherapy. J Acquir Immune Defic Syndr 1990; 3: 493.
21. De Clercy E. Potential drugs for the treatment of AIDS. J Antimicrob Chemother 1989; 23 [Suppl A]: 35.
22. Batinic D, Robey FA. The V3 region of the envelope glycoprotein of human immunodeficiency virus type I binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem 1992; 267: 6664.
23. Nagumo T, Hoshino H. Heparin inhibits infectivity of human immunodeficiency virus in vitro. Jpn J Cancer Res 1992; 79: 9.
24. Imai H, Yamada O, Morita S, Suehiro S, Kurimura T. Detection of HIV-1 RNA in heparinized plasma of HIV-1 seropositive individuals. J Virol Methods 1992; 36: 181.
25. Schols D, Baba M, Pauwels R, De Clercq E. Flow cytometric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+cells. J Acquir Immune Defic Syndr 1989; 2: 10.
26. Mitsuya H, Looney D, Kuno S, Uneo R, Wong-Staal F, Broder S. Dextran sulfate suppression of viruses in the HIV-1 family: inhibition of virion binding to CD4+ cells. Science 1988; 240: 646.
27. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro Proc Natl Acad Sci USA 1988; 85: 6132.
28. Mbemba E, Czyrski JA, Gattegno L. The interaction of a glycosaminoglycan, heparin, with HIV-1 major envelope glycoprotein. Biochim Biophys Acta 1992; 1180: 123.
29. Harrop HA, Rider CC, Coombe DR. Sulphated polysaccharides exert anti-HIV activity at differing sites. Biochem Soc Trans 1992; 20: 163.
30. Baba M, De Clercq E, Schols D, Pauwels R, Snoeck R, Van Boeckel C, Van Dedem G, Kraaijeveld N, Hobbelen P. Ottenheijm H. Novel sulfated polysaccharides: dissociation of antihuman immunodeficiency virus activity from antithrombin activity. J Infect Dis 1990; 161: 208.
31. Cardin AD, Taylor DL. Krstenansky JL, Tyms AS, Jackson RL. A heparin which binde, to the envelope glycoprotein gp120 inhibits human immunodeficiency virus replication. Trans Assoc Am Physicians 1989; 102: 101.
32. Parish CR, Low L, Warren HS, Cunningham AL. A polyanion binding site on the CD4 molecule. Proximity to the HIV-gp120 binding region. J Immunol 1990; 145: 1188.
33. Lanza P, Washington L, Zanetti M. A method to analyze the interaction between gp120 of human immunodeficiency virus and CD4. Viral Immunol 1992; 5: 305
34. Schols D, Pauwels R, Desmyter J, De Clercq E. Flow cytometric method to monitor the destruction of CD4+ cells following their fusion with HIV-infected cells. Cytometry 1990; 11: 736.
35. Mann DA. Frankel AD. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 1991; 10: 1733.
36. Rosenberg R, Bauer K. The heparin-antithrombin system: a natural anticoagulant mechanism In: Colman R, Hirsh J. Marder V, Salzman E (eds) Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott: 1994; 837-860.
37. Fera G, Semeraro M, De Mitrio V, Schiraldi O. Disseminated intravascular coagulation associated with cryptococcosis in a patient with immunodeficiency syndrome. Infection 1993; 21: 171.
38. Conn J, Lackner R, Wenig P, Pillari G. Deep venous thrombosis in patients with AIDS. NY State J Med 1990; 90: 159.